SEC For	m 4 FORM	4	UNITE	D STA	TES	S SE		ITIE	ES AN	DE	ЕХСНА	NGE	E CC	OMMI	SSION				
				Washington, D.C. 20549													OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERS											OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			11
					Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940														0.5
1. Name and Address of Reporting Person* BLICKENSTAFF KIM D					2. Issuer Name and Ticker or Trading Symbol <u>TANDEM DIABETES CARE INC</u> [TNDM]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify				vner
	st) (First) (Middle) O TANDEM DIABETES CARE, INC. 075 ROSELLE STREET					3. Date of Earliest Transaction (Month/Day/Year) 08/27/2021												below)	
(Street) SAN DIEGO CA 92121					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing Line) X Form filed by One Repor Form filed by More than Person									orting Perso	n			
(City)	(S	itate)	(Zip)																
		Tab	ole I - No	n-Deriv	ative	e Se	curities	s Ac	quired	, Dis	sposed o	f, or	Ben	eficiall	y Owned				
Date				Date	e E onth/Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A (D	A) or D)	Price	Reported Transactio (Instr. 3 an	on(s) Id 4)		0	nstr. 4)
Common Stock 0				08/27/	08/27/2021				M ⁽¹⁾		28,700		Α	\$3.5	231,0	231,090			ee ootnote ⁽²⁾
Common Stock														1,892			D		
		-	Table II -								osed of,				Owned				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any		A. Transaction Code (Instr. B)		S, Warrants 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			xerci	sable and te	7. Title and Ar of Securities Underlying Derivative Sec (Instr. 3 and 4)		Amount s ecurity 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	n c	or Number of Shares					
Series A Warrants	\$3.5	08/27/2021			м		28,700		10/17/20	17	10/17/2022	Com Sto		28,700	\$ <mark>3.5</mark>	0		D	

Explanation of Responses:

1. The transaction reflects the cash exercise of warrants to purchase common stock, at an exercise price of \$3.50.

2. The securities are held by the Kim Blickenstaff Revocable Trust dated April 15, 2010.

Remarks:

<u>s/ David B. Berger, Attorney-</u> <u>in-Fact for Kim D. Blickenstaff</u> 08/31/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.